The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization

Oncotarget

Volumn 6, Issue 29, 2015, Pages 26599-26614

  Zhou, Heng ^a,b,c,d,e,g   Forveille, Sabrina ^a,b,c,d,g   Sauvat, Allan ^a,b,c,d,g   Sica, Valentina ^a,b,c,d,e,g   Izzo, Valentina ^a,b,c,d,g   Durand, Sylvère ^a,b,c,d,g   Müller, Kevin ^a,b,c,d,e,g   Liu, Peng ^a,b,c,d,e,g   Zitvogel, Laurence ^a,e,f,g   Rekdal, Øystein ^g,h,i   Kepp, Oliver ^a,b,c,d,g   Kroemer, Guido ^{a,b,c,d,g,j,k}  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f INSERM   (France)

^g Center of Clinical Investigations in Biotherapies of Cancer CICBT 507   (France)

^h LYTIX BIOPHARMA AS   (Norway)

ⁱ UNIVERSITY OF TROMSØ   (Norway)

^j HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^k KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Cancer; LTX 315; Mitochondrial membrane permeabilization; Mitophagy; Necrosis

Indexed keywords

ANTINEOPLASTIC AGENT; LTX 315 PEPTIDE; MITOCHONDRIAL PROTEIN; PROTEIN BAK; PROTEIN BAX; UNCLASSIFIED DRUG; BAK1 PROTEIN, HUMAN; BAK1 PROTEIN, MOUSE; BAX PROTEIN, HUMAN; BAX PROTEIN, MOUSE; BCL2 PROTEIN, HUMAN; LTX-315; OLIGOPEPTIDE; PARKIN; PEPTIDE; PROTEIN BCL 2; UBIQUITIN PROTEIN LIGASE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL MEMBRANE PERMEABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; EMBRYO; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MITOPHAGY; MOUSE; NONHUMAN; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; ANIMAL; APOPTOSIS; CHEMISTRY; CYTOSOL; DRUG EFFECTS; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; HCT 116 CELL LINE; INTRACELLULAR MEMBRANE; KNOCKOUT MOUSE; METABOLISM; NEOPLASM; PERMEABILITY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CYTOSOL; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; INTRACELLULAR MEMBRANES; MASS SPECTROMETRY; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, KNOCKOUT; MICROSCOPY, FLUORESCENCE; MITOCHONDRIA; MITOCHONDRIAL DEGRADATION; NEOPLASMS; OLIGOPEPTIDES; PEPTIDES; PERMEABILITY; PROTO-ONCOGENE PROTEINS C-BCL-2; UBIQUITIN-PROTEIN LIGASES;

EID: 84944463400     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5613     Document Type: Article

References (36)

1. Ward PS and Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer cell. 2012; 21:297-308.
2. Galluzzi L, Kepp O and Kroemer G. Mitochondria: master regulators of danger signalling. Nature reviews Molecular cell biology. 2012; 13:780-788.
3. Tan AS, Baty JW, Dong LF, Bezawork-Geleta A, Endaya B, Goodwin J, Bajzikova M, Kovarova J, Peterka M, Yan B, Pesdar EA, Sobol M, Filimonenko A, Stuart S, Vondrusova M, Kluckova K, et al. Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA. Cell metabolism. 2015; 21:81-94.
4. Maiuri MC and Kroemer G. Essential role for oxidative phosphorylation in cancer progression. Cell metabolism. 2015; 21:11-12.
5. Gogvadze V, Orrenius S and Zhivotovsky B. Mitochondria as targets for chemotherapy. Apoptosis: an international journal on programmed cell death. 2009; 14:624-640.
6. Fulda S, Galluzzi L and Kroemer G. Targeting mitochondria for cancer therapy. Nature reviews Drug discovery. 2010; 9:447-464.
7. Fulda S. Targeting apoptosis for anticancer therapy. Seminars in cancer biology. 2015; 31:84-88.
8. Wirotius JM and Bourjade C. [Palliative treatment of urinary incontinence]. Soins; la revue de reference infirmiere. 1989; :37-44.
9. Green DR and Kroemer G. The pathop hysiology of mitochondrial cell death. Science. 2004; 305:626-629.
10. Green DR, Galluzzi L and Kroemer G. Cell biology. Metabolic control of cell death. Science. 2014; 345:1250256.
11. Zitvogel L, Galluzzi L, Smyth MJ and Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity. 2013; 39:74-88.
12. Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buque A, Castro MG, Cirone M, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2014; 3:e955691.
13. Golden EB, Frances D, Pellicciotta I, Demaria S, Helen Barcellos-Hoff M and Formenti SC. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology. 2014; 3:e28518.
14. Calvet CY, Famin D, Andre FM and Mir LM. Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cells. Oncoimmunology. 2014; 3:e28131.
15. Sukkurwala AQ, Adjemian S, Senovilla L, Michaud M, Spaggiari S, Vacchelli E, Baracco EE, Galluzzi L, Zitvogel L, Kepp O and Kroemer G. Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set. Oncoimmunology. 2014; 3:e28473.
16. Michaud M, Sukkurwala AQ, Di Sano F, Zitvogel L, Kepp O and Kroemer G. Synthetic induction of immunogenic cell death by genetic stimulation of endoplasmic reticulum stress. Oncoimmunology. 2014; 3:e28276.
17. de Mejia EG and Dia VP. The role of nutraceutical proteins and peptides in apoptosis, angiogenesis, and metastasis of cancer cells. Cancer metastasis reviews. 2010; 29:511-528.
18. Yin CM, Wong JH, Xia J and Ng TB. Studies on anticancer activities of lactoferrin and lactoferricin. Current protein & peptide science. 2013; 14:492-503.
19. Eliassen LT, Berge G, Leknessund A, Wikman M, Lindin I, Lokke C, Ponthan F, Johnsen JI, Sveinbjornsson B, Kogner P, Flaegstad T and Rekdal O. The antimicrobial peptide, lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo. International journal of cancer Journal international du cancer. 2006; 119:493-500.
20. Camilio KA, Rekdal O and Sveinbjornsson B. LTX-315 (Oncopore): A short synthetic anticancer peptide and novel immunotherapeutic agent. Oncoimmunology. 2014; 3:e29181.
21. Macho A, Decaudin D, Castedo M, Hirsch T, Susin SA, Zamzami N and Kroemer G. Chloromethyl-X-Rosamine is an aldehyde-fixable potential-sensitive fluorochrome for the detection of early apoptosis. Cytometry. 1996; 25:333-340.
22. Metivier D, Dallaporta B, Zamzami N, Larochette N, Susin SA, Marzo I and Kroemer G. Cytofluorometric detection of mitochondrial alterations in early CD95/Fas/APO-1-triggered apoptosis of Jurkat T lymphoma cells. Comparison of seven mitochondrion-specific fluorochromes. Immunology letters. 1998; 61:157-163.
23. Penninger JM and Kroemer G. Mitochondria, AIF and caspases--rivaling for cell death execution. Nature cell biology. 2003; 5:97-99.
24. Kroemer G, Galluzzi L and Brenner C. Mitochondrial membrane permeabilization in cell death. Physiological reviews. 2007; 87:99-163.
25. West AP, Khoury-Hanold W, Staron M, Tal MC, Pineda CM, Lang SM, Bestwick M, Duguay BA, Raimundo N, MacDuff DA, Kaech SM, Smiley JR, Means RE, Iwasaki A and Shadel GS. Mitochondrial DNA stress primes the antiviral innate immune response. Nature. 2015; 520:553-557.
26. von Haefen C, Gillissen B, Hemmati PG, Wendt J, Guner D, Mrozek A, Belka C, Dorken B and Daniel PT. Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway. Oncogene. 2004; 23:8320-8332.
27. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB and Korsmeyer SJ. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 2001; 292:727-730.
28. Pedro JM, Wei Y, Sica V, Maiuri MC, Zou Z, Kroemer G and Levine B. BAX and BAK1 are dispensable for ABT-737-induced dissociation of the BCL2-BECN1 complex and autophagy. Autophagy. 2015; 11:452-459.
29. Levine B and Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008; 132:27-42.
30. Youle RJ and Narendra DP. Mechanisms of mitophagy. Nature reviews Molecular cell biology. 2011; 12:9-14.
31. Galluzzi L, Bravo-San Pedro JM and Kroemer G. Organelle-specific initiation of cell death. Nature cell biology. 2014; 16:728-736.
32. Kimura S, Fujita N, Noda T and Yoshimori T. Monitoring autophagy in mammalian cultured cells through the dynamics of LC3. Methods in enzymology. 2009; 452:1-12.
33. Narendra D, Tanaka A, Suen DF and Youle RJ. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. The Journal of cell biology. 2008; 183:795-803.
34. Durcan TM and Fon EA. The three 'P's of mitophagy: PARKIN, PINK1, and post-translational modifications. Genes & development. 2015; 29:989-999.
35. Kuwana T, Mackey MR, Perkins G, Ellisman MH, Latterich M, Schneiter R, Green DR and Newmeyer DD. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell. 2002; 111:331-342.
36. Kushnareva Y, Andreyev AY, Kuwana T and Newmeyer DD. Bax activation initiates the assembly of a multimeric catalyst that facilitates Bax pore formation in mitochondrial outer membranes. PLoS biology. 2012; 10:e1001394.